INVO Bioscience Inc (NASDAQ: INVO) stock fell -4.97% on Monday to $1.72 against a previous-day closing price of $1.81. With 0.61 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.7 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $1.9100 whereas the lowest price it dropped to was $1.7100. The 52-week range on INVO shows that it touched its highest point at $24.79 and its lowest point at $0.50 during that stretch. It currently has a 1-year price target of $2.00. Beta for the stock currently stands at 1.44.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INVO was up-trending over the past week, with a rise of 6.83%, but this was up by 218.52% over a month. Three-month performance surged to 14.67% while six-month performance fell -74.71%. The stock lost -92.89% in the past year, while it has lost -79.71% so far this year. A look at the trailing 12-month EPS for INVO yields -12.41 with Next year EPS estimates of -0.29. For the next quarter, that number is -0.87. This implies an EPS growth rate of 66.28% for this year and 95.22% for next year.
Float and Shares Shorts:
At present, 2.47 million INVO shares are outstanding with a float of 2.45 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.29 million, which was 11.71% higher than short shares on Sep 28, 2023. In addition to Mr. Steven M. Shum as the firm’s CEO & Director, Mr. Andrea Goren serves as its Chief Financial Officer.
Other institutions hold 11.99% of INVO, in contrast to 0.94% held by mutual funds. As the largest shareholder in INVO with 9.36% of the stake, Sabby Management LLC holds 231,023 shares worth 231,023. A second-largest stockholder of INVO, Citadel Securities LLC, holds 36,194 shares, controlling over 1.47% of the firm’s shares. AWM Investment Co., Inc. is the third largest shareholder in INVO, holding 32,000 shares or 1.30% stake. With a 0.49% stake in INVO, the Fidelity Extended Market Index Fu is the largest stakeholder. A total of 12,191 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.21% of INVO stock, is the second-largest Mutual Fund holder. It holds 5,277 shares valued at 6596.0. Perritt Ultra Micro Cap Fund holds 0.15% of the stake in INVO, owning 3,650 shares worth 4563.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for INVO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With INVO analysts setting a high price target of $2.00 and a low target of $2.00, the average target price over the next 12 months is $2.00. Based on these targets, INVO could surge 16.28% to reach the target high and rise by 16.28% to reach the target low. Reaching the average price target will result in a growth of 16.28% from current levels.
Summary of Insider Activity:
Insiders traded INVO stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.